Pharma Patent explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
The Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals (October 2014) were written so that examiners and Controllers apply uniform standards to drug-related applications. Paragraphs 1 to 6 give the background, scope, statutory provisions, the kinds of claims the Office meets, a note on Markush claims, the prior art search method and a first rule on what is an invention.
The Guidelines supplement the Manual and the biotechnology and traditional knowledge guidelines, and the Act and Rules prevail in any conflict (para 2). Pharmaceutical claims fall into five families: product, process, new property or use, method of treatment and selection (para 4.2). A Markush claim is checked against six conditions. The examiner searches by structure, name, CAS number, INN and class (para 5), and a bare use claim is not an invention (para 6). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from October 2014. Where it refers to appellate decisions of the IPAB, the Board has since been abolished and appeals go to the High Court; see our posts on IPAB dissolution and on section 117A, appeals to the High Court. For a pharma specification, see patent drafting and filing.
Why the Guidelines exist (paragraph 1)
Paragraph 1 is a history of pharmaceutical patenting in India, and the Guidelines give it at length. In summary: the 1911 Act allowed both product and process patents; committees in the 1950s led to amendments on working and compulsory licences; after the Ayyangar committee the Patents Act, 1970 allowed process patents only for drugs and foods, with shorter terms. After the TRIPS Agreement, the Act was amended in 1999, 2002 and 2005, with mail-box and exclusive marketing rights as transition measures; since 1 January 2005 product patents are available for pharmaceuticals, agrochemicals, foods and products of chemical reactions. The paragraph also records section 92A for compulsory licences for export of medicines, the Biological Diversity Act, 2002 and the 2005 amendment of section 10 to require disclosure of the source of biological material.
It ends with the Office's purpose: quality, consistency and uniformity in examination, and recognition that a bad patent is a burden while good patents promote innovation (1.17).
For the applicant, the history explains why section 3(d) and the public-health provisions sit beside the patent grant; our posts on section 3(d) and TRIPS and on the special rules for chemical and pharma inventions cover the law.
Scope (paragraph 2)
The Guidelines say they are supplemental to the Manual of Patent Office Practice and Procedure, the Biotechnology Guidelines and the Traditional Knowledge Guidelines. Their illustrations are not exhaustive and examiners must decide each case on its own facts. In any conflict the Act and Rules prevail, and the Guidelines are dynamic and will be updated.
The provisions covered (paragraph 3)
The Guidelines emphasise these provisions in pharmaceutical examination: section 2(1)(j) (invention), section 2(1)(ja) (inventive step), section 2(1)(ac) (industrial application), section 3(b), (c), (d), (e), (i), (j) and (p), and section 10(4) and 10(5) (sufficiency, the method of performing the invention that the applicant considers most suitable, claims, unity, clarity and support). Each is given its own paragraph later, and the later articles in this series take them in turn.
The kinds of claims (paragraph 4.2)
TaxClue's table of the five families the Guidelines list:
| Family | Includes |
|---|---|
| I. Product | New chemical entities; formulations and compositions; combinations, dosage; new forms of known substances (salts, esters, polymorphs, solvates, stereoisomers, metabolites, pro-drugs, conjugates, pure forms, particle size, complexes, derivatives); kits; product-by-process |
| II. Process or method of manufacture | Claims to making the compound or product |
| III. New property or use | Use claims, including second indications |
| IV. Method of treatment or diagnosis | Of humans and animals |
| V. Selection inventions | Relating to product and process |
The Guidelines say the explanations on novelty, inventive step and other tests apply across these families, with separate treatment where a different approach is needed.
Markush claims
A Markush claim covers a family of compounds, sometimes thousands or millions, through a structure with several functionally equivalent groups. The Guidelines note that such claims bring questions of novelty, non-obviousness, industrial applicability, sufficiency and plurality of inventions. The examiner checks six things in the specification.
- Does it disclose the most representative embodiments known to the applicant?
- Do the embodiments share a common use or property?
- Do they share a common structure?
- Are the physical or chemical properties of the representatives disclosed?
- Are tests on the representatives provided?
- For a product claim, is at least one process for preparing the compounds disclosed, enabling the whole scope?
If any of these is missing, the claim may be objected to under unity of invention and insufficiency. Common structure means a shared structure that occupies a large part of the compounds, or a smaller shared part that is structurally distinctive in light of the prior art. For fuller treatment see the later articles on sufficiency and unity.
The prior art search (paragraph 5)
The examiner is to frame a comprehensive strategy combining key words, classification and compound searches, and search both patent and non-patent databases. Compounds can be searched by molecular or structural formula, IUPAC name, CAS Registry Number, generic name (INN) and International Patent Classification (5.2). Because many pharmaceutical claims involve derivatives of known compounds, which usually have INNs, the examiner searches on any INN found in the specification (5.3). Where a second use is claimed as a product claim, the examiner asks the applicant for the INN of the substance and, failing that, finds it (5.4).
Practical point: give the INN, structure and CAS number of every known compound named in the specification. It helps the examiner find the closest prior art and avoids a later request.
What is an invention (paragraph 6)
Paragraph 6.1 reads section 2(1)(j) as confined, for pharmaceuticals, to products and processes for making compounds. Claims in the form "use of compounds in the treatment of ..." or "a known substance for a new disease" are not inventions because they claim neither a product nor a process; objections under section 3(i) and 3(d) follow. Paragraph 6.2 adds that finding a new property of a known substance does not make the substance novel or inventive, and that second use of compounds in the public domain needs care.
The Guidelines illustrate with an order of the IPAB, as cited in the Guidelines, concerning a second medical indication for known fumaric acid derivatives: the claims were amended to product claims but the objection of lack of novelty remained, the Controller refused and the Board upheld. Since the IPAB's abolition, appeals lie to the High Court; the Act and Rules as now in force prevail.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Which family of claim is this? | Claims in the proper form: product, process, or (where allowed) a form that is not a bare use claim |
| What is the closest prior art, found by structure, INN or CAS number? | Identification of each known compound, with INN |
| For a Markush claim, are the six conditions met? | Representatives, common use and structure, properties, test data and a preparation process |
| Is the claim an invention under section 2(1)(j)? | A product or process claim, not "use of X for disease Y" |
A worked example (invented)
Arogya Labs files "use of compound A for treating condition B", where compound A is a known antihypertensive. The examiner objects under paragraph 6.1 that the claim is neither a product nor a process, and raises section 3(i) and 3(d). Arogya has data showing that a new crystalline form of A has a significantly different property, and it redrafts to a claim to that form and its preparation process, supported by the data. Whether the form passes section 3(d) is the subject of the next articles in this series, but the claim is no longer a bare use claim.
Common lapses
- Filing use claims in the form the Guidelines call outside section 2(1)(j).
- Naming a known compound without its INN.
- Claiming a Markush family without test data for any representative.
- Omitting a preparation process for a product claim.
Need help with a pharmaceutical filing?
Pharmaceutical claims need to be framed in the right form from the start and supported by data. Our team can review your claim set and specification against these paragraphs before filing. See patent drafting and filing, and read next on how novelty is assessed for pharmaceutical claims.
Key takeaways
- The Guidelines supplement the Manual, and the Act and Rules prevail.
- Pharmaceutical claims fall into product, process, new property or use, treatment and selection families.
- Markush claims are tested against six conditions.
- The examiner searches by structure, name, CAS number, INN and classification.
- A bare use claim is not an invention under section 2(1)(j).
Read next
- Pharmaceutical Patent Guidelines 2014, paragraph 7: assessing novelty
- Pharmaceutical Patent Guidelines 2014, paragraph 10: section 3(d) efficacy
- Pharmaceutical Patent Guidelines 2014, paragraph 11: sufficiency, clarity and support
- Pharma Patents in India: Section 3(d) and TRIPS Compliance
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.